Published on in Vol 9, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16863, first published .
Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study

Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study

Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study

Journals

  1. Ryan P, Valencia J, Cuevas G, Troya J, Ramon C, Rodríguez A, Torres-Macho J, Muñoz-Gómez M, Canorea I, Vázquez-Morón S, Resino S. HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. International Journal of Drug Policy 2021;92:103134 View
  2. Scott N, Win T, Tidhar T, Htay H, Draper B, Aung P, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi K, Naing W, Aung K, Hellard M. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. The Lancet Regional Health - Western Pacific 2021;10:100129 View
  3. Draper B, Htay H, Pedrana A, Yee W, Howell J, Pyone Kyi K, Naing W, Sanda Aung K, Markby J, Easterbrook P, Bowring A, Aung W, Sein Y, Nwe N, Myint K, Shilton S, Hellard M. Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar. Liver International 2021;41(11):2578 View
  4. Rupasinghe D, Choi J, Kumarasamy N, Pujari S, Sun L, Merati T, Lee M, Kinh N, Kiertiburanakul S, Do C, Avihingsanon A, Ross J, Jiamsakul A. Viral hepatitis and the cascade of care among people living with HIV in the Asia‐Pacific. HIV Medicine 2022;23(9):959 View
  5. Yee W, Draper B, Myint K, Min W, Htay H, O’Keefe D, Hellard M. Access to needles and syringes and methadone maintenance therapy among people who inject drugs in Yangon, Myanmar: a qualitative study. Harm Reduction Journal 2022;19(1) View
  6. Boeke C, Adesigbin C, Adisa O, Agwuocha C, Akanmu M, Anartati A, Aung K, Azania A, Bello Nabe R, Budiman A, Chan Y, Chawla U, Fatchanuraliyah , Fernandes O, Grover G, Naing T, Ngo D, Ramers C, Regan S, Sindhwani S, Tandy G, Tint K, Nguyen K, Witschi M, McClure C. Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. BMJ Open 2022;12(12):e062745 View
  7. Draper B, Yee W, Shilton S, Bowring A, Htay H, Nwe N, Markby J, Kyi K, Easterbrook P, Naing W, Win T, Aung K, Howell J, Pedrana A, Hellard M. Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up. BMJ Open 2022;12(5):e059639 View
  8. Dimech W, Cabuang L, Davies K, Vincini G. Implementation of Novel Quality Assurance Program for Hepatitis C Viral Load Point of Care Testing. Viruses 2022;14(9):1929 View
  9. Win T, Draper B, Palmer A, Htay H, Sein Y, Shilton S, Kyi K, Hellard M, Scott N. Cost‐effectiveness of a decentralized, community‐based “one‐stop‐shop” hepatitis C testing and treatment program in Yangon, Myanmar. JGH Open 2023;7(11):755 View
  10. Yee W, Bowring A, Draper B, O’Keefe D, Htay H, Myint K, Aung H, Win Y, Sein Y, Mary M, Lin A, Pedrana A, Hellard M, Probandari A. Patients’ access to and acceptance of community-based hepatitis C testing and treatment in Myanmar: A mixed-method study. PLOS Global Public Health 2023;3(6):e0000902 View
  11. Rennert L, Howard K, Kickham C, Gezer F, Coleman A, Roth P, Boswell K, Gimbel R, Litwin A. Implementation of a mobile health clinic framework for Hepatitis C virus screening and treatment: a descriptive study. The Lancet Regional Health - Americas 2024;29:100648 View
  12. Hauner A, Onwuchekwa C, Ariën K. Sample-to-result molecular diagnostic platforms and their suitability for infectious disease testing in low- and middle-income countries. Expert Review of Molecular Diagnostics 2024;24(5):423 View